Off-the-Shelf Anti-CD19 CAR T-cell Therapy With Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
Friday, May 15, 2026 1 min read
Key Takeaway: The article discusses the efficacy and tolerability of an off-the-shelf anti-CD19 CAR T-cell therapy in patients with systemic lupus erythematosus. The therapy shows promising results with reduced or no conditioning chemotherapy, which may facilitate better patient outcomes. The findings support plans for enrolling adolescents in future clinical trials.
Price reaction · baseline $1.9 (2026-05-14 close) · hit pre-market · clean, no other FATE news in the window
day 0 close
-7.6%
day 1 · peak
-8.9%
day 3
-3.2%
Market Sentiment Analysis
POSITIVE FACTORS
Demonstrated efficacy of the therapy in systemic lupus erythematosus.
Reduced or no conditioning chemotherapy enhances tolerability.
Supports planned enrollment of adolescents in upcoming studies.
Full Press Release Details
• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Frequently Asked Questions
What is the focus of the CAR T-cell therapy study?
The study focuses on the efficacy and tolerability of off-the-shelf anti-CD19 CAR T-cell therapy in systemic lupus erythematosus.
How does the therapy affect chemotherapy use?
The therapy demonstrates efficacy with reduced or no conditioning chemotherapy, improving tolerability.
What future plans are mentioned in the article?
The article mentions plans for enrolling adolescents in upcoming clinical trials.